

# FILGOTINIB

2017

FITZROY

Phase 2/ Filgotinib/ CD / Induction

Conclusion:

**Filgotinib induced clinical remission in significantly more patients with active Crohn's disease compared with placebo, and had an acceptable safety profile.**

2021

SELECTION

Phase 2b/3/ Filgotinib/ UC/ Induction & Maintain

Conclusion

**Filgotinib 200 mg was efficacious inducing and maintaining clinical remission in patients with moderate-severe UC compared to placebo.**

2023

DIVERGENCE 1

Phase 2/ Filgotinib/ small bowel CD/ Induction

Conclusion

**24 weeks of treatment with filgotinib not better than placebo in the proportion of patients who achieved clinical remission, SB MaRIA remission, or MaRIA remission in any of the SB segments.**